YOLFTbeta
30

Shandong Keyuan Pharmaceutical Co. Ltd. A

301281 · SHE · Healthcare / Drug Manufacturers - General

38.45CNY-1.26 (-3.17%)

Price History

Full chart

Market Stats

Previous Close39.71
Open39.88
Day Range38.25 – 41.20
52-Week Range25.84 – 59.24
Volume2.36M
Market Cap5.12B
P/E (TTM)135.00
Forward P/E0.00
EPS0.35
Dividend Yield0.11%
Beta0.19
50-Day Avg43.85
200-Day Avg40.72

About

Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clarithromycin L-lactate; chlorpheniramine maleate; esmolol hydrochloride; isoproterenol hydrochloride; nicotinamide-tinidazole; aminolevulinate; nisoldipine; qupibutu; propafenone hydrochloride; potassium diclofenac; chlorzoxazone; esomeprazole sodium; palonosetron hydrochloride; idalafeng; piroxicam; phenylephrine; vildagliptin; parecoxib sodium; and ruxolitinib hydrochloride. Shandong Keyuan Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Jinan, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEOMs. Kun Qin C.P.A.
  • Employees650
  • HeadquartersKeyuan Street, Jinan, China, 251601, China
  • Websitehttps://www.keyuanpharm.com

Leadership

  • Ms. Kun Qin C.P.A.VP & Board Secretary · b. 1983

Financials

Income Statement

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue420.89M442.87M447.58M463.72M398.23M
Growth (%)-+5.22%+1.07%+3.60%-14.12%
Cost of Revenue243.69M261.57M236.09M258.43M185.42M
Gross Profit177.20M181.29M211.49M205.28M212.80M
Gross Margin42.10%40.94%47.25%44.27%53.44%
Operating Expense87.06M82.68M145.82M143.66M168.22M
Operating Income90.14M98.62M65.67M61.62M44.58M
Operating Margin21.42%22.27%14.67%13.29%11.20%
EBITDA-132.25M114.62M112.61M68.77M
EBITDA Margin-29.86%25.61%24.28%17.27%
Net Income78.17M91.28M77.04M60.45M16.55M
Net Income Margin18.57%20.61%17.21%13.04%4.16%
R&D24.43M26.97M43.86M35.82M42.35M
R&D as % of Total Revenue5.80%6.09%9.80%7.72%10.63%
Interest Expense---36.59K16.57K
Interest Expense % of Total Revenue---0.01%0.00%

Balance Sheet

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets559.51M651.79M1.47B1.55B1.69B
Total Liabilities128.52M132.06M138.93M192.87M331.48M
Total Equity430.98M519.73M1.33B1.36B1.36B
Cash66.01M148.97M325.22M178.13M359.08M

Cash Flow

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow52.02M115.86M37.03M-60.52M43.47M
Capital Expenditure20.19M31.11M70.15M296.38M137.05M
Free Cash Flow31.83M84.75M-33.12M-356.90M-93.58M
Dividends Paid--30.94M32.56M24.82M
FCF to OCF61.18%73.15%-89.43%589.76%-215.28%
Dividend Paid to FCF---93.43%-9.12%-26.52%

Earnings

Report DateJun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------
EPS Actual0.180.140.100.200.130.030.190.210.18-0.10-0.140.280.32
Surprise-------------
Timing-------------

Key Statistics & Ratios

Market Cap5.12B
Enterprise Value5.38B
Trailing P/E135.00
Forward P/E0.00
Price / Sales10.20
Price / Book3.79
EPS0.35
Book Value13.20
Revenue (TTM)501.83M
Gross Profit (TTM)254.99M
EBITDA93.36M
Profit Margin7.68%
Operating Margin17.92%
Return on Equity2.72%
Return on Assets1.68%
Shares Outstanding108.29M
Shares Float57.01M
Beta0.19
Dividend Yield0.11%
Dividend Rate0.05
Payout Ratio14.04%

Dividends

20261×
0.05Jun 16, 2026
20251×
0.20May 20, 2025
20241×
0.30Apr 30, 2024
20231×
0.40May 26, 2023

Stock Splits

  • May 26, 20231.4:1